CN114344482A - Multifunctional nanoparticle based on metal organic framework and preparation method and application thereof - Google Patents
Multifunctional nanoparticle based on metal organic framework and preparation method and application thereof Download PDFInfo
- Publication number
- CN114344482A CN114344482A CN202210042321.2A CN202210042321A CN114344482A CN 114344482 A CN114344482 A CN 114344482A CN 202210042321 A CN202210042321 A CN 202210042321A CN 114344482 A CN114344482 A CN 114344482A
- Authority
- CN
- China
- Prior art keywords
- organic framework
- metal organic
- nanoparticles
- preparation
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the technical field of nano-drug presentation systems and contrast agents, in particular to a multifunctional nanoparticle based on a metal organic framework, and a preparation method and application thereof. A multifunctional nanoparticle based on a metal organic framework comprises the metal organic framework, wherein a medicine AQ4N activated under an anoxic condition is loaded on the metal organic framework and is modified with polydopamine. The nanoparticles can solve the technical problem of unsatisfactory curative effect caused by tumor tissue hypoxia in the process of pure photothermal or photodynamic therapy, are a multi-stimulation inertial sequence response nano system, can overcome the inherent defects of multiple biological barriers and a single-stimulation response system, and have great application value in the aspect of noninvasive diagnosis and treatment of tumors.
Description
Technical Field
The invention relates to the technical field of nano-drug presentation systems and contrast agents, in particular to a multifunctional nanoparticle based on a metal organic framework, and a preparation method and application thereof.
Background
Light-based therapies such as photothermal therapy (PTT) and photodynamic therapy (PDT) have received much attention in cancer therapy because of their advantages such as non-invasive, high temporal and spatial accuracy, controllability, negligible drug resistance, and local treatment. Although light-based therapies have received much attention in cancer treatment, it remains a significant challenge to improve the specificity and effectiveness of such therapies. The self-maladjustment of the tumor and abnormal physicochemical tumor microenvironment, hypoxia, acid pH value and the like caused by irregular vascularity induce or participate in drug resistance generation and metastasis of the tumor, the effect of cancer treatment is seriously influenced, and most tumor patients are caused to relapse and die. Since photodynamic therapy relies strictly on tissue oxygen to produce reactive oxygen species, the sustained availability of tissue oxygen and the vascular occlusive effect further exacerbate hypoxia, thereby limiting its effectiveness. Photothermal therapy is an oxygen-independent therapeutic paradigm that kills cancer cells by near-infrared light exciting local hyperthermia induced by a photothermal agent. While photothermal therapy is effective for tumor ablation, hyperthermia has been found to cause an exacerbation of the hypoxic levels in the tumor microenvironment due to uneven heat transfer, excessive temperatures in the tumor region, and the potential for radiation damage to the skin or tumor recurrence.
In recent years, the intelligent nano material developed aiming at the tumor pathological characteristics can specifically respond or release the anti-tumor drug to exogenous stimulation (light, ultrasonic waves and temperature) or endogenous stimulation signals (hypoxia, pH value and hydrogen peroxide) at tumor sites, can obviously improve the anti-cancer effect and reduce side effects. However, most therapies require the synergistic use of a combination of drugs, antibodies, inhibitors and gene chains, and sequential release at the appropriate time and place, which is a huge challenge for these single stimuli-responsive nano-platforms. Therefore, a multi-stimulus inertial sequence response nano system is urgently needed to overcome multiple biological barriers and overcome the inherent defects of a single stimulus response system. More specifically, in the course of photothermal or photodynamic therapy, cancer cells are easy to initiate a self-protection pathway related to hypoxia, and there is a need to develop a multifunctional drug presentation system which can effectively control the release of drugs and overcome the hypoxia stress response of cancer cells caused by photothermal or photodynamic therapy.
Disclosure of Invention
The invention aims to provide a multifunctional nanoparticle based on a metal organic framework, and aims to solve the technical problem that cancer cells easily start a self-protection way related to hypoxia in the process of photo-thermal or photodynamic therapy, so that the curative effect is not ideal.
In order to achieve the purpose, the invention adopts the following technical scheme:
the multifunctional nanoparticle based on the metal organic framework comprises the metal organic framework, wherein AQ4N is loaded on the metal organic framework, and the surface of the metal organic framework is modified with polydopamine.
The scheme also provides a preparation method of the multifunctional nanoparticles based on the metal organic framework, which comprises the following steps of:
preparation of S1 metal organic framework: dispersing 4-carboxyl phenyl porphyrin, zirconium oxychloride octahydrate and benzoic acid into N, N' -dimethylformamide, and incubating under a stirring condition to obtain a metal organic framework;
loading of S2 drug: mixing AQ4N and a metal organic framework, and incubating in dark under stirring to obtain drug-loaded nanoparticles;
s3 polydopamine modification: and mixing the drug-loaded nanoparticles with dopamine hydrochloride, and stirring in an alkaline solution in a dark condition to obtain the poly-dopamine-modified drug-loaded nanoparticles.
The scheme also provides the application of the multifunctional nanoparticles based on the metal organic framework in the preparation of antitumor drugs.
The scheme also provides an application of the multifunctional nanoparticles based on the metal organic framework in preparing an imaging agent.
The principle and the advantages of the scheme are as follows: in the technical scheme, a polydopamine-modified porphyrin-based metal organic framework and a chemotherapeutic drug AQ4N activated under an anoxic condition are reasonably integrated to form a nano-drug diagnosis and treatment system, so that photothermal and photodynamic therapy, chemotherapy and diagnosis of tumors are realized. In the nanoparticles, a porphyrin-based metal organic framework (PCN-224) with high photosensitizer loading and easy diffusion of singlet oxygen is used as a template, polydopamine is modified on the surface of the metal organic framework to form the nanoparticles, the photo-thermal function of the metal organic framework is increased, and the dispersibility and stability of the nanoparticles in the systemic circulation are improved. After the metal organic framework PCN-224 is loaded with the chemotherapeutic prodrug AQ4N, the chemotherapeutic prodrug AQ4N reaches tumor tissues under 660nm laser irradiation to realize photothermal and photodynamic therapy, and simultaneously polydopamine is degraded in a low-pH tumor microenvironment to quickly release the drug AQ4N, so that AQ4N is quickly activated to play an antitumor role in the tumor hypoxia environment caused by the phototherapy, and finally, the inertial sequence cooperative therapy of three modes of tumor photothermal, photodynamic and hypoxia activation chemotherapy can be realized.
The advantages of the present solution over the prior art are specifically stated as follows:
(1) existing research data indicate that photothermal and photodynamic therapy cause an increase in the hypoxic levels in the tumor microenvironment. In the technical scheme, the hypoxia activated prodrug is introduced, so that the phototherapy-based treatment scheme is further optimized. AQ4N used in this protocol is a novel bioreductive prodrug that can be activated to toxic AQ4 for bioreductive chemotherapy under hypoxic conditions. Thus, a combination of oxygen-consuming phototherapy and a light-aggravated hypoxia-activated AQ4N prodrug is an effective strategy to enhance the treatment of cancer with traditional phototherapy, reducing the potential phototoxicity in preclinical models.
(2) Nanometallic organic frameworks (MOFs) composed of clusters linked by metal ions or organic ligands have found wide application in gas storage, catalysis, sensing, and drug delivery, due to their highly customizable nature of metal ions and organic linkers. MOFs have the characteristics of high drug-loading rate, internal biodegradability, structure/component adjustability, controllable size/shape and the like, and are preferred materials for preparing nano materials for biomedical application. MOFs can be used as good carriers for sonosensitizers or photosensitizers, thereby realizing sonodynamic and photodynamic therapy. However, the poor biocompatibility and potential toxicity of MOFs limits their use as drug carriers for in vivo tumor therapy. In the technical scheme, a porphyrin-based metal organic framework (PCN-224) is used as a template, polydopamine is modified on the basis of the metal framework, the dispersibility and stability of the nanoparticles in systemic circulation are improved, the toxicity is reduced, and the biocompatibility of the nanoparticles is improved.
(3) In order to achieve more ideal tumor treatment effect, a novel diagnosis and treatment integrated drug presentation system based on a metal organic framework needs to be developed urgently. The nanoparticles can realize photothermal and photodynamic therapy at the same time, can realize drug slow release in a tumor acidic microenvironment, and activate a chemotherapy prodrug AQ4N under an anoxic condition caused by phototherapy so as to exert cytotoxicity, are a multi-stimulus and inertial-sequence response nano system, and can overcome the inherent defects of multiple biological barriers and a single-stimulus response system.
In general, this multifunctional nanosystem has several important properties: the components are simple and nontoxic, easy self-assembly can be realized, and a multifunctional and highly biocompatible nano platform is generated; the photodynamic photo-thermal combination therapy is realized by using single-wavelength laser (660nm), so that the treatment time is shortened, the treatment steps are simplified, and the treatment effect and the safety are improved; in a tumor microenvironment, AQ4N is efficiently released and is quickly activated under the condition of hypoxia induced by phototherapy to play an anti-tumor role; under the guidance of noninvasive and accurate PA imaging, the safety and the effectiveness of the treatment process are high. Therefore, the nanosystems of the present scheme have considerable potential in achieving image-guided and multi-stimulus responsive tumor photochemotherapy.
Further, the mass ratio of AQ4N to the metal organic framework is 0.5-1.5: 0.5-1.5. With the above mass ratios, a sufficient amount of AQ4N can be loaded on the metal organic framework to exert its anti-tumor effect.
Further, the raw materials of the metal organic framework comprise, by mass, 100 mg: 300 mg: 2.8g of 4-carboxyphenylporphyrin, zirconium oxychloride octahydrate and benzoic acid.
Further, in S1, 4-carboxyphenylporphyrin, zirconium oxychloride octahydrate, benzoic acid and N, N' -dimethylformamide are used in an amount ratio of 100 mg: 300 mg: 2.8 g: 100 ml.
The metal organic framework synthesized by the raw materials has ideal acoustodynamic and photodynamic effects, and can be used as a medicine carrying framework to realize the loading of polydopamine and AQ 4N.
Further, in S1, the incubation temperature was 85-95 ℃ and the incubation time was 5 hours. At the above incubation times, sufficient loading of AQ4N on the metal organic framework was achieved.
Further, in S2, the incubation time was 24 to 48 hours without light. Under the incubation time, the full load of the polydopamine on the AP NPs can be realized.
Further, in S3, the dosage ratio of the drug-loaded nanoparticles to dopamine hydrochloride is: 1:0.8-2.0, the volume ratio of the absolute ethyl alcohol to the deionized water is 3:4, and the stirring time is 24-48 h. By adopting the dosage ratio of the drug-loaded nanoparticles to the dopamine hydrochloride, the final product can be ensured to obtain more ideal photo-thermal conversion performance. When the mass ratio of dopamine hydrochloride to AP NPs is changed between 0.2 and 0.8, the photo-thermal heating effect of the corresponding nanoparticles is gradually increased along with the increase of the addition of dopamine hydrochloride, namely the photo-thermal conversion efficiency is gradually increased. However, when the mass ratio of the two components reaches 0.8 or more and reaches 0.8, the photothermal conversion efficiency does not significantly increase any more, and is stabilized at about 30%.
Drawings
FIG. 1 is a transmission electron micrograph of nanoparticles of Experimental example 1 of the present invention.
FIG. 2 is a scanning electron micrograph of nanoparticles of Experimental example 1 of the present invention.
FIG. 3 is a graph showing a distribution of particle diameters of nanoparticles of Experimental example 1 of the present invention.
FIG. 4 is a potential diagram of nanoparticles of Experimental example 1 of the present invention.
Fig. 5 is a graph of the photo-thermal conversion temperature rise of nanoparticles prepared in example 1 of experimental example 2 of the present invention under 660nm laser irradiation.
Fig. 6 shows the photo-thermal stability test of nanoparticles prepared in example 1 of experimental example 2 of the present invention under 660nm laser irradiation.
FIG. 7 shows the temperature change of nanoparticles under 660nm laser irradiation when the mass ratio of dopamine hydrochloride to AP NPs in Experimental example 2 is 0.2.
FIG. 8 shows the temperature change of nanoparticles under 660nm laser irradiation when the mass ratio of dopamine hydrochloride to AP NPs in Experimental example 2 is 0.4.
FIG. 9 is a drug release profile of nanoparticles of Experimental example 3 of the present invention under acidic conditions.
FIG. 10 is a graph showing the active oxygen generation curve of nanoparticles of Experimental example 4 of the present invention under 660nm laser irradiation.
FIG. 11 is a diagram showing the effect of CCK8 method on the toxicity of nanoparticles on 4T1 breast cancer cells and HUVEC cells in Experimental example 5 of the present invention.
FIG. 12 is a diagram illustrating the effect of different treatment groups on the activity of 4T1 breast cancer cells evaluated by the CCK8 method in Experimental example 5 of the present invention.
Fig. 13 is an in vitro photoacoustic imaging effect image of nanoparticles of different concentrations in experimental example 6 of the present invention.
FIG. 14 shows the results of photoacoustic imaging quantitative evaluation in vivo in the nanoparticle mouse according to Experimental example 6 of the present invention.
FIG. 15 shows the trend of tumor size after subcutaneous tumor transplantation in mice treated by different treatment groups of Experimental example 7.
FIG. 16 shows the ex vivo tumor mass after treatment of subcutaneous tumor transplants in mice of different treatment groups of Experimental example 7 of the present invention.
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the following examples and experimental examples are conventional means well known to those skilled in the art, and the materials, reagents and the like used therein are commercially available.
Example 1: preparation of multifunctional nanoparticles based on metal organic framework
100mg of 4-carboxyphenylporphyrin (TCPP), 300mg of zirconium oxychloride octahydrate (ZrOCl)2·8H2O), 2.8g benzoic acid (benzoic acid), dispersed in 100ml N, N' -Dimethylformamide (DMF), stirred for 5h, 12 ℃ at 90 ℃ (optional temperature range 85-90 ℃)Centrifuging at 000rpm for 10min for purification, and collecting the centrifuged solid phase to obtain the metal organic framework. AQ4N and the aqueous solution of the metal organic framework were stirred at room temperature in the dark for 24h, and centrifuged to obtain AP NPs (PCN-224@ AQ 4N). Wherein, in the aqueous solution, the mass ratio of AQ4N to the metal organic framework is 1:1 (optional mass ratio is 0.5-1.5:0.5-1.5), and the concentration of the metal organic framework in the aqueous solution is 1 mg/mL.
10mg of AP NPs are taken and dispersed into absolute ethyl alcohol-water solution (15ml,3:4, v: v), ultrasonic dispersion is carried out for 4min (optional time range is 3-5min) (65%, 40KHz), then 15mg (optional range is 8-10mg) of dopamine hydrochloride is added, wherein the mass ratio of the AP NPs to the dopamine hydrochloride is maintained at 1: 0.8-1.0. Magnetically stirring for 8min (optional range of 5-10min), and adding 20ml (optional range of 10-30ml) of Tris-HCl with pH of 8.5-8.8 to the mixture to adjust the pH of the mixture to 8.5. Stirring (600rpm) in the dark for 24h (optional range is 24-48 h). The obtained product is centrifuged at 12000rpm (optional range is 10000-.
Example 2: preparation of drug-free nanoparticles (PP NPs)
100mg of 4-carboxyphenylporphyrin (TCPP), 300mg of zirconium oxychloride octahydrate (ZrOCl)2·8H2O), 2.8g benzoic acid (benzoic acid), dispersed in 100ml N, N' -Dimethylformamide (DMF), stirred at 90 ℃ for 5h, centrifuged at 12000rpm for 10min for purification, and the centrifuged solid phase was taken to obtain a metal-organic framework.
Dispersing 10mg of metal organic framework into an absolute ethyl alcohol-water solution (15ml,3:4, v: v), performing ultrasonic dispersion for 4min (65%, 40KHz), and adding 15mg of dopamine hydrochloride, wherein the mass ratio of the metal organic framework to the dopamine hydrochloride is maintained at 1: 0.8-2.0. Magnetically stirring for 8min, adding 20ml of Tris-HCl with pH value of 8.5-8.8 to the mixture to adjust the pH value of the mixture to be alkaline 8.5, and stirring in dark (600rpm) for 24 h. The obtained product is centrifuged at 12000rpm for 15min to obtain PP NPs.
Experimental example 1: characterization of multifunctional nanoparticles
The surface morphology of the nanoparticles of example 1 was observed according to conventional methods of the prior art, and the transmission electron microscope image is shown in fig. 1, and the scanning electron microscope image is shown in fig. 2. The particle size and Zeta potential of the nanoparticles of example 1 were measured and the particle size and potential profiles are shown in fig. 3 and 4, respectively. The nanoparticles prepared in example 1 had a particle size of 91. + -. 5.5nm and a surface potential of-7.8. + -. 0.8 mV. Encapsulation efficiency and drug loading were measured with reference to the following methods: encapsulation efficiency (% w/w) — (drug/drug addition in nanocomposite) × 100%; the drug loading (% w/w) × (total mass of drug/nanocomposite in nanocomposite) × 100%. The encapsulation efficiency of AQ4N was 49.16%, and the drug loading was 19.98%.
PCN-224@ AQ4N nanoparticles with different drug loading (DLC%) and encapsulation efficiency (DLE%) were prepared by incubating PCN-224 and AQ4N for 24h (see example 1 for the preparation method of AP NPs). When the mass ratio of the PCN-224 to the AQ4N is changed between 1.25 and 0.5, the drug loading percentages of the PCN-224@ AQ4N nanoparticles are respectively 17.93%, 18.50%, 19.98%, 19.76% and 19.29% with the increase of the addition amount of AQ4N, and the drug loading percentages are in a trend of decreasing after increasing. The encapsulation efficiencies corresponding to drug loading rates exhibited decreasing trends of 87.43%, 56.48%, 49.16%, 46.35%, and 37.73%, respectively. Based on the above results, nanoparticles with drug loading of 19.98% and encapsulation efficiency of 49.16% were selected for subsequent experiments, wherein the mass ratio of PCN-224 to AQ4N was 1: 1. Generally, the drug loading rate increases with increasing amounts of drug added, but the drug loading rate slips off after a certain amount of AQ4N is added. This shows that the dosage relationship between PCN-224 and AQ4N and the effect is not consistent with the conventional cognition in the field, and the inventor analyzes that the drug loading of AQ4N has a downward sliding phenomenon because the excessive addition of AQ4N has a certain negative effect on the surface adsorption performance of PCN-224.
Experimental example 2: testing of photothermal conversion efficiency
The test of the photothermal conversion efficiency was performed as follows:
1) the nanoparticles (prepared in example 1) were diluted to different concentrations (50, 100,200, 300, 400. mu.g/mL) by double distilled water, added to a sample cell of transparent quartz glass tubes, 1mL per tube, and irradiated by 660nm laser (0.8W/cm)25min), monitoring its temperature using a near infrared thermal imagerAnd (6) changing and recording.
2) Adding 1mL of nanoparticles 50 μ g/mL into a sample cell of a transparent quartz glass tube, and irradiating with 660nm laser at irradiation intensities of 0.5, 0.66, 0.8, and 1W/cm2Irradiating for 5min, and using double distilled water with the same volume as the reference; the temperature change was monitored and recorded using a near infrared thermal imager.
3) Adding 1mL of nanoparticles 50 μ g/mL into a sample cell of a transparent quartz glass tube, and irradiating with 660nm laser (1W/cm)2) And monitoring the temperature of the nanoparticles when the laser irradiation is started to reach the stable temperature of the nanoparticles by using a thermal imaging instrument, then closing the laser instrument, continuously monitoring the temperature of the nanoparticles, and stopping monitoring and recording when the nanoparticles reach the room temperature. From the above results, the photothermal conversion efficiency η is calculated by a formula of the related art (see formula (1)).
The photo-thermal conversion test result of the nanoparticles under 660nm laser irradiation is shown in detail in fig. 5, and the photo-thermal stability test result of the nanoparticles under 660nm laser irradiation is shown in fig. 6. The results show that the nanoparticles prepared in example 1 have good photothermal conversion efficiency (30%) and photothermal stability.
In order to achieve the optimal photothermal conversion performance of the nanoparticles, the AP NPs and dopamine hydrochloride were stirred for 24 hours according to different mass ratios to prepare corresponding nanoparticles (see example 1), and the photothermal conversion effect of the obtained nanoparticles was observed. When the mass ratio of dopamine hydrochloride to AP NPs is changed between 0.2 and 0.8, the photo-thermal heating effect of the corresponding nanoparticles is gradually increased along with the increase of the addition of dopamine hydrochloride, namely the photo-thermal conversion efficiency is gradually increased. However, when the mass ratio of the two components reaches 0.8 or more and reaches 0.8, the photothermal conversion efficiency does not significantly increase any more, and is stabilized at about 30%. Fig. 7 shows the temperature change of the nanoparticles under 660nm laser irradiation when the mass ratio of dopamine hydrochloride to AP NPs is 0.2, and fig. 8 shows the temperature change of the nanoparticles under 660nm laser irradiation when the mass ratio of dopamine hydrochloride to AP NPs is 0.4.
Experimental example 3: drug Release Performance test
A dialysis bag (1000Da) containing 10mL of nanoparticles (200ug/mL) was immersed in 40mL of PBS solution (pH 6.5 or 7.4, 37 ℃) and stirred. 3ml of PBS was extracted every 2min and supplemented with an equal amount of PBS. The amount of AQ4N released was measured by uv spectrophotometry (standard curve method).
The results of the experiment are detailed in fig. 9, and the results show that: after the nanoparticles were incubated under acidic conditions for 10min, about 19.7 ± 0.41% AQ4N was released from the nanoparticles, whereas there was almost no drug release from the nanoparticles for the pH 7.4 group.
Experimental example 4: active oxygen Generation ability test
4T1 cells were cultured in a confocal dish for 24h, each well was replaced with 1ml of medium without drug, medium with free PCN224, serum-free medium with nanoparticles (50. mu.g), incubated for 4h, PBS washed unbound nanoparticles, and added DCFH-DA (1. mu.M) for 30 min. The group containing nanoparticles without laser treatment was set as a control group. PBS washing, medium replacement, and subsequent 660 mW/cm laser of 5 mW/cm-2Irradiating for 5min, and detecting green fluorescence signal at 488nm excitation wavelength under a laser confocal microscope.
The results of the experiment are detailed in fig. 10, and the results show that: the APP NPs and the laser group 4T1 cells show stronger green fluorescence under a confocal microscope, which indicates that the APP NPs in the tumor cells generate Reactive Oxygen Species (ROS) in a large amount after light activation. While the remaining groups showed weaker fluorescence signals.
Experimental example 5: in vitro cytotoxicity assessment
The specific procedure for in vitro cytotoxicity assessment was as follows:
1)4T1 cells and HUVEC cells (1X 10)4) The culture was performed in 96-well plates for 12h, different concentrations of APP NPs (0,10,25,50,100, 200. mu.g/mL) were added to each well, the incubation was performed for 4h, and the unbound nanoparticles were washed with PBS. The culture is continued for 24h, and the safety of different nanoparticles to two kinds of cells is analyzed by a CCK8 method. The results of the experiment are detailed in FIG. 11, showing: the nanoparticles have no obvious killing effect on HUVEC cells and mouse breast cancer cells, and reflect the preparationThe nanoparticles have higher safety in cell experiments.
2)4T1 cell (1X 10)4) Cultured in 96-well plates for 12h, divided into five groups: the kit comprises a pure laser group, a pure AQ4N group, an APP NPs combined laser irradiation group (normoxia), a PP NPS combined laser irradiation group (hypoxemia, no AQ4N) and an APP NPS combined laser irradiation group (hypoxemia), wherein corresponding nanoparticles are added into each group, a hypoxic bag is used for forming under the hypoxic condition, incubation is carried out for 4h, and PBS cleans uncombined nanoparticles. The laser irradiation group was subjected to 660nm laser irradiation (0.8W/cm)2And 5min) for 24h, and analyzing the survival rate of the breast cancer cells after different groups of treatment by adopting a CCK8 method. The results of the experiment are shown in detail in FIG. 12, where the concentrations refer to the concentrations of the experimental set of nanoparticles. The results show that: under laser irradiation, the APP NPs group has the largest killing effect on 4T1 cells, and the capacity of phototherapy combined with hypoxia-induced chemotherapy for killing breast cancer cells at a cell level is reflected.
Experimental example 6: in vitro and in vivo photoacoustic imaging effect study
In-vitro photoacoustic imaging, APP NPs (0.10,0.25,0.50,1.00,2.00mg/mL) with different concentrations are added into an agarose gel model prepared in advance, a small animal photoacoustic imaging system is used for scanning, the excitation wavelength is 690nm, and the relationship between photoacoustic signals and APP NPs concentrations is evaluated. In vivo photoacoustic imaging was observed using 4T1 tumor-bearing mice injected intravenously with APP NPs (200. mu.L, 10 mg/kg). And scanning photoacoustic images corresponding to mouse tumor tissues at different time points (0h, 6h, 12h, 24h and 48h) by using a photoacoustic instrument after injection.
The results of the experiments are detailed in fig. 13 and 14, and the results show that: the result of in vitro photoacoustic imaging shows that the APP NPs nanoparticles have obvious photoacoustic signals, the signal intensity of the APP NPs nanoparticles is linearly increased along with the concentration, the linear relation is good, and a foundation is laid for in vivo imaging research; the result of in vivo photoacoustic imaging shows that along with the prolonging of time, the photoacoustic signal of the tumor part of the tumor-bearing mouse gradually increases, reaches a peak value 12h after injection, and then gradually decreases, thus prompting that the nanoparticle is used as a photoacoustic imaging contrast agent for observing and detecting the tumor of the mouse.
Experimental example 7: experiment of in vivo therapeutic Effect
After establishing the mouse in-situ breast cancer model, randomly dividing the mice into six groups: 1. control group: injecting 200 mu L PBS through tail vein; 2. laser irradiation group: irradiating the tumor region by using near-infrared laser with the wavelength of 660 nm; group of APP NPs: APP NPs (200 mu L, calculated by the mass of the nanoparticles, the dosage is 10mg/kg) are injected through tail veins; AQ4N set: after 12 hours, the tumor area is irradiated by laser with the wavelength of 660nm (0.8W,5min) after the tail vein injection of AQ4N solution (200 muL, 0.15 mg/mL; 5.PP NPs + laser group, 200 muL, dosage is 10mg/kg by mass of nanoparticles), and after the treatment is finished, the mouse continues to feed and monitors the change of the tumor volume and the survival time of the mouse.
The results of the experiments are detailed in fig. 15 and 16, and the results show that: on day 14 post-treatment, tumors disappeared completely in the APP NPs combined laser irradiated group of mice, and tumors grew to different degrees in the remaining five groups of mice.
The foregoing is merely an example of the present invention and common general knowledge in the art of designing and/or characterizing particular aspects and/or features is not described in any greater detail herein. It should be noted that, for those skilled in the art, without departing from the technical solution of the present invention, several variations and modifications can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicability of the patent. The scope of the claims of the present application shall be determined by the contents of the claims, and the description of the embodiments and the like in the specification shall be used to explain the contents of the claims.
Claims (10)
1. A multifunctional nanoparticle based on a metal organic framework is characterized in that: the metal organic framework is loaded with AQ4N, and the surface of the metal organic framework is modified with polydopamine.
2. The multifunctional nanoparticle based on a metal organic framework according to claim 1, wherein: the mass ratio of AQ4N to the metal organic framework is 0.5-1.5: 0.5-1.5.
3. The multifunctional nanoparticle based on a metal organic framework according to claim 2, wherein: the raw materials of the metal organic framework comprise, by mass, 100 mg: 300 mg: 2.8g of 4-carboxyphenylporphyrin, zirconium oxychloride octahydrate and benzoic acid.
4. The preparation method of the multifunctional nanoparticle based on metal organic framework as claimed in claim 3, wherein the preparation method comprises the following steps: comprises the following steps in sequence:
preparation of S1 metal organic framework: dispersing 4-carboxyl phenyl porphyrin, zirconium oxychloride octahydrate and benzoic acid into N, N' -dimethylformamide, and incubating under a stirring condition to obtain a metal organic framework;
loading of S2 drug: mixing AQ4N and a metal organic framework, and incubating in dark under stirring to obtain drug-loaded nanoparticles;
s3 polydopamine modification: and mixing the drug-loaded nanoparticles with dopamine hydrochloride, and stirring in an alkaline solution in a dark condition to obtain the poly-dopamine-modified drug-loaded nanoparticles.
5. The preparation method of the multifunctional nanoparticle based on metal organic framework as claimed in claim 4, wherein the preparation method comprises the following steps: in S1, the ratio of the amounts of 4-carboxyphenylporphyrin, zirconium oxychloride octahydrate, benzoic acid and N, N' -dimethylformamide is 100 mg: 300 mg: 2.8 g: 100 ml.
6. The method for preparing multifunctional nanoparticles based on metal-organic framework as claimed in claim 5, wherein the incubation temperature is 85-95 ℃ and the incubation time is 5h in S1.
7. The method for preparing multifunctional nanoparticles based on metal-organic frameworks (MOFs) according to claim 6, wherein the incubation time in S2 is 24-48h away from light.
8. The preparation method of the multifunctional nanoparticles based on the metal-organic framework as claimed in claim 6, wherein in S3, the dosage ratio of the drug-loaded nanoparticles to dopamine hydrochloride is as follows: 1:0.8-2.0, the volume ratio of the absolute ethyl alcohol to the deionized water is 3:4, and the stirring time is 24-48 h.
9. Use of the multifunctional nanoparticle based on metal organic framework according to any one of claims 1 to 3 in preparation of antitumor drug.
10. Use of a multifunctional nanoparticle based on a metal organic framework according to any of claims 1 to 3 for the preparation of an imaging agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210042321.2A CN114344482B (en) | 2022-01-14 | 2022-01-14 | Multifunctional nanoparticle based on metal-organic framework and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210042321.2A CN114344482B (en) | 2022-01-14 | 2022-01-14 | Multifunctional nanoparticle based on metal-organic framework and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114344482A true CN114344482A (en) | 2022-04-15 |
| CN114344482B CN114344482B (en) | 2023-05-12 |
Family
ID=81090528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210042321.2A Active CN114344482B (en) | 2022-01-14 | 2022-01-14 | Multifunctional nanoparticle based on metal-organic framework and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114344482B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252788A (en) * | 2022-06-02 | 2022-11-01 | 燕山大学 | Multi-mode anti-tumor nano-drug carrier, drug delivery system, and preparation method and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087913A1 (en) * | 2008-04-10 | 2012-04-12 | Lee Ruey-Min | Induction of tumor hypoxia for cancer therapy |
| CN109091677A (en) * | 2017-06-21 | 2018-12-28 | 上海交通大学医学院 | The multifunction invisible nanoparticle of cRGDfK peptide modified total load VP and AQ4N a kind of and its application |
| CN109985247A (en) * | 2019-04-03 | 2019-07-09 | 河南科技学院 | A kind of preparation method of the hybridized metal organic framework compounds for drug release |
| CN110025596A (en) * | 2019-04-25 | 2019-07-19 | 上海理工大学 | A kind of Nano composite granules and preparation method thereof |
| CN111494339A (en) * | 2020-04-24 | 2020-08-07 | 东南大学 | Application of cancer cell membrane bionic nano reactor AGZ @ CM in preparation of anti-cancer drugs |
| CN111840546A (en) * | 2019-04-11 | 2020-10-30 | 华东理工大学 | Hypoxia activated prodrug combined phototherapy targeting nanoparticle |
| CN113262300A (en) * | 2021-03-29 | 2021-08-17 | 武汉科技大学 | Nanoparticle for mitochondrion targeted delivery of photosensitizer PCN-224, and preparation method and application thereof |
| CN113368056A (en) * | 2021-04-29 | 2021-09-10 | 重庆医科大学 | Carrier-free nano delivery system loaded with carnosol anthraquinone and preparation method thereof |
| CN113476424A (en) * | 2021-07-15 | 2021-10-08 | 深圳大学 | Composite nano-medicine and preparation method and application thereof |
-
2022
- 2022-01-14 CN CN202210042321.2A patent/CN114344482B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087913A1 (en) * | 2008-04-10 | 2012-04-12 | Lee Ruey-Min | Induction of tumor hypoxia for cancer therapy |
| CN109091677A (en) * | 2017-06-21 | 2018-12-28 | 上海交通大学医学院 | The multifunction invisible nanoparticle of cRGDfK peptide modified total load VP and AQ4N a kind of and its application |
| CN109985247A (en) * | 2019-04-03 | 2019-07-09 | 河南科技学院 | A kind of preparation method of the hybridized metal organic framework compounds for drug release |
| CN111840546A (en) * | 2019-04-11 | 2020-10-30 | 华东理工大学 | Hypoxia activated prodrug combined phototherapy targeting nanoparticle |
| CN110025596A (en) * | 2019-04-25 | 2019-07-19 | 上海理工大学 | A kind of Nano composite granules and preparation method thereof |
| CN111494339A (en) * | 2020-04-24 | 2020-08-07 | 东南大学 | Application of cancer cell membrane bionic nano reactor AGZ @ CM in preparation of anti-cancer drugs |
| CN113262300A (en) * | 2021-03-29 | 2021-08-17 | 武汉科技大学 | Nanoparticle for mitochondrion targeted delivery of photosensitizer PCN-224, and preparation method and application thereof |
| CN113368056A (en) * | 2021-04-29 | 2021-09-10 | 重庆医科大学 | Carrier-free nano delivery system loaded with carnosol anthraquinone and preparation method thereof |
| CN113476424A (en) * | 2021-07-15 | 2021-10-08 | 深圳大学 | Composite nano-medicine and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| SHI-YING LI 等: "Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy", BIOMATERIALS * |
| WEI ZHANG 等: "Photochemically-driven highly efficient intracellular delivery and light/ hypoxia programmable triggered cancer photo-chemotherapy", JOURNAL OF NANOBIOTECHNOLOGY * |
| ZHIMEI HE 等: "Hybrid Nanomedicine Fabricated from Photosensitizer- T erminated Metal–Organic Framework Nanoparticles for Photodynamic Therapy and Hypoxia-Activated Cascade Chemotherapy", SMALL * |
| 蓝善优 等: "肿瘤微环境响应的智能纳米载体在肿瘤光动力治疗中的应用", 中国激光 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252788A (en) * | 2022-06-02 | 2022-11-01 | 燕山大学 | Multi-mode anti-tumor nano-drug carrier, drug delivery system, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114344482B (en) | 2023-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Recent advances of cancer chemodynamic therapy based on Fenton/Fenton-like chemistry | |
| Zheng et al. | Nanoscale mixed-component metal–organic frameworks with photosensitizer spatial-arrangement-dependent photochemistry for multimodal-imaging-guided photothermal therapy | |
| Pucelik et al. | Recent advances in strategies for overcoming hypoxia in photodynamic therapy of cancer | |
| Zhu et al. | Free radical as a double-edged sword in disease: Deriving strategic opportunities for nanotherapeutics | |
| Zhuang et al. | Sequential ultrasound-triggered and hypoxia-sensitive nanoprodrug for cascade amplification of sonochemotherapy | |
| Zhou et al. | Advances in photosensitizer-related design for photodynamic therapy | |
| Feng et al. | Biodegradable oxygen-producing manganese-chelated metal organic frameworks for tumor-targeted synergistic chemo/photothermal/photodynamic therapy | |
| Zhou et al. | Multifunctional nanoreactors-integrated microneedles for cascade reaction-enhanced cancer therapy | |
| CN113599520B (en) | Porphyrin lipid-perfluorocarbon nano preparation and preparation method and application thereof | |
| CN108452303A (en) | It is a kind of to carry double medicine nanometer formulations and preparation method thereof | |
| Yakubovskaya et al. | Experimental photodynamic therapy: 15 years of development | |
| CN111150853B (en) | Preparation and application of drug carrier for combined treatment of tumors | |
| Yang et al. | A Nd 3+ sensitized upconversion nanosystem with dual photosensitizers for improving photodynamic therapy efficacy | |
| CN113018267B (en) | Unsaturated fatty acid-photosensitizer co-assembled nanoparticles and construction method and application thereof | |
| Liu et al. | Current advances in metal–organic frameworks for cancer nanodynamic therapies | |
| Xu et al. | Photodynamic therapy based on porphyrin-based metal–organic frameworks | |
| CN114344482B (en) | Multifunctional nanoparticle based on metal-organic framework and preparation method and application thereof | |
| Wang et al. | Trace-Water-Induced Competitive Coordination Synthesis and Functionalization of Porphyrinic Metal–Organic Framework Nanoparticles for Treatment of Hypoxic Tumors | |
| Yi et al. | Manipulate tumor hypoxia for improved photodynamic therapy using nanomaterials | |
| Shi et al. | Nanoscale Metal–Organic Frameworks Combined with Metal Nanoparticles and Metal Oxide/Peroxide to Relieve Tumor Hypoxia for Enhanced Photodynamic Therapy | |
| Xu et al. | Carbon dots as a promising therapeutic approach for combating cancer | |
| Kang et al. | Applications of nanocomposites based on zeolitic imidazolate framework-8 in photodynamic and synergistic anti-tumor therapy | |
| Liang et al. | Emerging nitric oxide gas‐assisted cancer photothermal treatment | |
| CN111686250A (en) | Mitochondrion targeted photothermal therapeutic agent and preparation and application thereof | |
| CN114601925B (en) | Hyaluronic acid and RSL3 co-modified photosensitive nanomaterial, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |